The Agreement began on April 1, 2001. The agreement offers significant value to Consorta members through a wide variety of service and support programs, while providing significant business potential to Nycomed Amersham Imaging. Nycomed Amersham is the world leader in brachytherapy seed implants, used to treat prostate cancer.
Prostate cancer is the most common form of cancer in men.
According to the National Cancer Institute, over 198,000 men will be diagnosed with prostate cancer in 2001, and nearly 32,000 men will die from the disease. An estimated 8 out of 10 men diagnosed with prostate cancer are over 65. Currently, it is estimated that approximately 40,000 prostate cancer patients will be treated using seed implants in 2001. About Nycomed Amersham Imaging Nycomed Amersham Imaging is committed to finding innovative diagnostic and therapeutic solutions in cardiology, pulmonology, neurology and oncology. The Company is part of Nycomed Amersham plc, the world leader in in-vivo diagnostic imaging and life sciences.